Southlake, TX – According to filings with the U.S. Securities and Exchange Commission, OncoNano Medicine is raising $60,000,000.00 in new funding. Sources indicate as part of senior management Interim CEO, Alvaro Guillem played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About OncoNano Medicine

OncoNano Medicine is developing a new class of products that exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery and T-cell activating immunotherapies.

To learn more about OncoNano Medicine, visit http://www.onconanomed.com/

Contact:
Alvaro Guillem, Interim CEO
682-285-1411

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved